-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
May 2019
-
Scott Antonia, MD, PhD
Posted: May 27, 2019 Scott Antonia, MD, PhD, was appointed director of the newly formed DCI Center for Cancer Immunotherapy at Duke Cancer Institute. In addition to his leadership role, Dr. […]
-
Charles B. Simone, II, MD
Posted: May 27, 2019 Charles B. Simone, II, MD, has joined the New York Proton Center, which is opening this spring, as its chief medical officer. In his previous position, Dr. […]
-
FDA’s New Acting Commissioner
Posted: May 27, 2019 After Scott Gottlieb’s resignation as commissioner of the U.S. Food and Drug Administration (FDA) in early March, the Secretary of Health and Human Services Alex M. Azar […]
-
Howard (Jack) West, MD
Posted: May 27, 2019 Howard (Jack) West, MD, has moved from the Swedish Cancer Institute in Seattle, where he directed the medical oncology component of thoracic oncology program, to City of […]
-
Lorlatinib’s Role in ROS1-Positive Lung Cancer
By Alice Shaw, MD, PhD Posted: May 27, 2019 On November 2, 2018, lorlatinib, a potent and central nervous system (CNS)–penetrant next-generation ALK/ROS1 inhibitor, was granted accelerated approval by the U.S. […]